Emcure Pharmaceuticals Limited is an Indian pharmaceutical company headquartered in Pune, Maharashtra. It was founded in 1981 by Satish Mehta. The company focuses on developing, manufacturing, and marketing a broad range of pharmaceutical products. Here are some key points about Emcure Pharmaceuticals…
- Product Range: Emcure manufactures a variety of pharmaceutical products including tablets, capsules, injectables, and APIs (Active Pharmaceutical Ingredients). The company’s product portfolio spans multiple therapeutic areas such as cardiology, pain and analgesics, HIV, gynecology, nephrology, and anti-infectives.
- Global Presence: Emcure has a significant presence in over 70 countries across the globe. It operates subsidiaries in several countries, including the United States, Canada, Brazil, and the UK.
- Research and Development: Emcure places a strong emphasis on R&D and innovation. It operates several R&D facilities that focus on the development of new drugs, complex generics, and biosimilars. The company invests heavily in research to bring new and effective treatments to the market.
- Biosimilars: Emcure is a key player in the biosimilars segment. Biosimilars are biologic medical products that are almost identical copies of an original product that is manufactured by a different company. Emcure has developed several biosimilars, which are marketed in various countries.
- Corporate Social Responsibility (CSR): Emcure is involved in various CSR activities, focusing on healthcare, education, and community development. The company runs several initiatives aimed at improving access to healthcare and supporting education for underprivileged communities.
- Recent Developments: Emcure has been active in the development of treatments for COVID-19. The company has been involved in manufacturing and supplying antiviral drugs and has also worked on the development of a COVID-19 vaccine in collaboration with other organizations.
- Leadership: The company is led by Satish Mehta, the founder, and Managing Director, along with a team of experienced professionals who oversee various aspects of the business.
Emcure Pharmaceuticals continues to grow and expand its reach, focusing on innovation and quality in the pharmaceutical industry.
Emcure Pharmaceuticals Limited IPO Tentative Timetable
Particular | Date |
IPO Open Date | 03 July 2024 |
IPO Close Date | 05 July 2024 |
Allotment Date | 08 July 2024 |
IPO Listing Date | 10 July 2024 |
Emcure Pharmaceuticals Limited IPO Details
Issue Type | Book Built Issue IPO |
Face Value | Rs. 10 Per Equity Share |
IPO Price | Rs. 960 to Rs. 1008 Per Equity Share |
Market Lot | 14 Share |
ISIN Code | |
Listing At | NSE, & BSE |
Issue Size | Approx. Rs. 1952 Crore. |
Emcure Pharmaceuticals Limited IPO Lot Size
Application | Lots | Shares | Amount |
Minimum | 1 | 14 | Rs. 14112 |
Maximum | 14 | 196 | Rs. 197568 |
Small HNI (Minimum) | 15 | 210 | Rs. 211680 |
Big HNI (Minimum) | 71 | 994 | Rs. 1001952 |
Emcure Pharmaceuticals Limited IPO Allotment Status
Click Here To Check IPO Allotment Status Emcure Pharmaceuticals Limited IPO
Click Here To Get ASBA Forms Emcure Pharmaceuticals Limited IPO
Company Financials:
Particular | 31 March 2024 | 31 March 2023 | 31 March 2022 |
Total Assets | 7806.16 | 6672.53 | 6063.47 |
Total Revenue | 6715.24 | 6031.72 | 5918.86 |
Profit After Tax | 527.58 | 561.85 | 702.56 |
Company Promoters:
Satish Mehta and Sunil Mehta are the company promoters.
Objects of this Issue:
- Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the company.
- General corporate purposes.
Registrar & Company Details
Company Contact Information | IPO Registrar |
Emcure Pharmaceuticals Limited Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune -411 057 Phone: +91 20 3507 0033 Email: investors@emcure.co.in Website: https://www.emcure.com | Link Intime India Private Ltd Phone: +91-22-4918 6270 Email: emcure.ipo@linkintime.co.in Website: https://linkintime.co.in/initial_offer/public-issues.html |